Results 221 to 230 of about 308,174 (298)

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, EarlyView.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

HIV-DRIVES: HIV drug resistance identification, variant evaluation, and surveillance pipeline. [PDF]

Access Microbiol
Kanyerezi S, Sserwadda I, Ssemaganda A, Seruyange J, Ayitewala A, Oundo HR, Tenywa W, Kagurusi BA, Tusabe G, Were S, Ssewanyana I, Nabadda S, Namaganda MM, Mboowa G.   +13 more
europepmc   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China. [PDF]

Pharmaceuticals (Basel)
Zhang J, Sun B, Sheng Z, Ding X, Fan Q, Huang G, Guo Z, Zhong P, Liao L, Xing H, Xia Y, Chai C, Jiang J.   +12 more
europepmc   +1 more source

Human Islet

Cell Proliferation, EarlyView.
Jiaqi Zou, Shen Li, Hongxing Fu, Mei Zhang, Anbin Hu, Xiaohui Tian, Yuanyuan Du, Lingling Wei, Xuchun Chen, Jie Gao, Rui Liang, Xinshun Feng, Yang Li, Ying Wang, Xiangheng Cai, Peng Sun, Xuejie Ding, Boya Zhang, Tengli Liu, Na Liu, Jie Hao, Lei Wang, Hongling Zhao, Jiani Cao, Aijin Ma, Lijun Zhu, Qiyuan Li, Qiang Wei, Xiaoming Ding, Ying Cheng, Tongbiao Zhao, Shusen Wang   +31 more
wiley   +1 more source

Prevalence of low‐level viremia and its association with virological failure among adolescents living with HIV in Eastern Cape, South Africa

HIV Medicine, EarlyView.
Abstract Objectives Low‐level viremia (LLV) has been associated with an increased risk of virological failure among adults on antiretroviral therapy (ART). However, evidence on the clinical implications of LLV among adolescents living with HIV remains limited.
Zea Leon, Olanrewaju Edun, Siyanai Zhou, Janke Tolmay, Lucie Cluver, Gayle Sherman, Ahmad H. Mazanderani, Elona Toska   +7 more
wiley   +1 more source

HIV Drug Resistance in Newly Diagnosed Young Children in the Western Cape, South Africa. [PDF]

Pediatr Infect Dis J
Anderson K, van Zyl G, Hsiao NY, Claassen M, Mudaly V, Voget J, Heekes A, Kalk E, Phelanyane F, Boulle A, Sridhar G, Ragone L, Vannappagari V, Davies MA.   +13 more
europepmc   +1 more source

Bret/BRAT

Critical Quarterly, EarlyView.
Nicholas Smart
wiley   +1 more source

Scaling HIV self‐testing to improve health equity among cisgender gay, bisexual and other men who have sex with men, trans and gender‐diverse people in the United Kingdom: An HIV self‐testing implementation action framework

HIV Medicine, EarlyView.
Abstract Background HIV self‐testing (HIVST) is feasible, highly acceptable and can increase HIV testing uptake/frequency without harm while also reducing costs. Despite HIVST's benefits, UK service provision has been sporadic partially due to policymakers and commissioners' reluctance over concerns about linkage to care/surveillance, which ultimately ...
T. Charles Witzel, Peter Weatherburn, Fiona M. Burns, Isaac Y.‐H. Chu, Phil Samba, Alison J. Rodger   +5 more
wiley   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, EarlyView.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source